{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:51:23Z","timestamp":1787320283207,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472198"],"award-info":[{"award-number":["82472198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02052-3","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:17:02Z","timestamp":1771899422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and therapies of multi-organ immune related adverse events"],"prefix":"10.1007","volume":"26","author":[{"given":"Dawei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xutong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"6","key":"2052_CR1","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","volume":"66","author":"MS von Itzstein","year":"2020","unstructured":"von Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor Immune-Related adverse event prediction and diagnosis. Clin Chem. 2020;66(6):779\u201393.","journal-title":"Clin Chem"},{"issue":"3","key":"2052_CR2","doi-asserted-by":"publisher","first-page":"e201611","DOI":"10.1001\/jamanetworkopen.2020.1611","volume":"3","author":"CY Chang","year":"2020","unstructured":"Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM, Van Boemmel-Wegmann S, Lo-Ciganic WH. Immune checkpoint inhibitors and Immune-Related adverse events in patients with advanced melanoma: A systematic review and network Meta-analysis. JAMA Netw Open. 2020;3(3):e201611.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2052_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"key":"2052_CR4","unstructured":"National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"2052_CR5","unstructured":"Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology (CSCO). Toxicity management guidelines related to immune checkpoint Inhibitors. 2019 [J]. People\u2019s Health Electronic Audio and Video Publishing Co.Ltd.; 2019."},{"issue":"1","key":"2052_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392. https:\/\/doi.org\/10.1038\/s41467-022-27960-2. PMID: 35046403; PMCID: PMC8770784.","journal-title":"Nat Commun"},{"issue":"9","key":"2052_CR7","doi-asserted-by":"publisher","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","volume":"2","author":"D Hsiehchen","year":"2019","unstructured":"Hsiehchen D, Watters MK, Lu R, Xie Y, Gerber DE. Variation in the assessment of immune-Related adverse event Occurrence, Grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw Open. 2019;2(9):e1911519.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2052_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","volume":"7","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Chronic Immune-Related adverse events following adjuvant Anti-PD-1 therapy for High-risk resected melanoma. JAMA Oncol. 2021;7(5):744\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2052_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"2052_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Xu Y, Zhao J, Zhong W, Wang M. Risk factors for immune-related adverse events: what have we learned and what Lies ahead? Biomark Res. 2021;9(1):79.","journal-title":"Biomark Res"},{"issue":"10","key":"2052_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-20-0372","volume":"8","author":"M Dougan","year":"2020","unstructured":"Dougan M. Understanding and overcoming the inflammatory toxicities of immunotherapy. Cancer Immunol Res. 2020;8(10):1230\u20135.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2052_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-021-00923-w","volume":"13","author":"E Hayase","year":"2021","unstructured":"Hayase E, Jenq RR. Role of the intestinal Microbiome and microbial-derived metabolites in immune checkpoint Blockade immunotherapy of cancer. Genome Med. 2021;13(1):107.","journal-title":"Genome Med"},{"issue":"3\u20134","key":"2052_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000509081","volume":"106","author":"D K\u00f6nig","year":"2021","unstructured":"K\u00f6nig D, L\u00e4ubli H. Mechanisms of immune-Related complications in cancer patients treated with immune checkpoint inhibitors. Pharmacology. 2021;106(3\u20134):123\u201336.","journal-title":"Pharmacology"},{"issue":"12","key":"2052_CR14","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, et al. Multisystem immune-Related adverse events associated with immune checkpoint inhibitors for treatment of Non-Small cell lung cancer. JAMA Oncol. 2020;6(12):1952\u20136.","journal-title":"JAMA Oncol"},{"issue":"9","key":"2052_CR15","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.6004\/jnccn.2020.7567","volume":"18","author":"G Kichenadasse","year":"2020","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, et al. Multiorgan Immune-Related adverse events during treatment with Atezolizumab. J Natl Compr Canc Netw. 2020;18(9):1191\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2052_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Management of Immunotherapy-Related Toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2052_CR17","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2052_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"4","key":"2052_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/biomedicines10040790","volume":"10","author":"R Vaddepally","year":"2022","unstructured":"Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP, Mathew N, Garje R, Chandra AB. Review of Immune-Related adverse events (irAEs) in Non-Small-Cell lung cancer (NSCLC)-Their Incidence, Management, multiorgan irAEs, and Rechallenge. Biomedicines. 2022;10(4):790.","journal-title":"Biomedicines"},{"issue":"8","key":"2052_CR20","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00262-020-02555-2","volume":"69","author":"IS Okoye","year":"2020","unstructured":"Okoye IS, Xu L, Walker J, Elahi S. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint Blockade. Cancer Immunol Immunother. 2020;69(8):1423\u201336.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2052_CR21","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cam4.5050","volume":"12","author":"J Longinow","year":"2023","unstructured":"Longinow J, Zmaili M, Skoza W, Kondoleon N, Marquardt R, Calabrese C, Funchain P, Moudgil R. Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series. Cancer Med. 2023;12(3):2281\u20139.","journal-title":"Cancer Med"},{"issue":"1","key":"2052_CR22","doi-asserted-by":"publisher","first-page":"e200177","DOI":"10.1212\/NXI.0000000000200177","volume":"11","author":"C Nelke","year":"2023","unstructured":"Nelke C, Pawlitzki M, Kerkhoff R, Schroeter CB, Aktas O, Neuen-Jacob E, Polzin A, Meuth SG, Ruck T. Immune checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis responsive to complement Blockade. Neurol Neuroimmunol Neuroinflamm. 2023;11(1):e200177.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2052_CR23","doi-asserted-by":"publisher","first-page":"1036603","DOI":"10.3389\/fcvm.2022.1036603","volume":"9","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chen Y, Xie J, Liu D, Hong X. Multisystem immune-related adverse events due to toripalimab: two cases-based review. Front Cardiovasc Med. 2022;9:1036603.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"2052_CR24","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","volume":"145","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019;145(6):1527\u201357.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"2052_CR25","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3390\/cancers14122995","volume":"14","author":"AM Kuo","year":"2022","unstructured":"Kuo AM, Kraehenbuehl L, King S, Leung DYM, Goleva E, Moy AP, Lacouture ME, Shah NJ, Faleck DM. Contribution of the Skin-Gut axis to Immune-Related adverse events with Multi-System involvement. Cancers (Basel). 2022;14(12):2995.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2052_CR26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00432-022-04425-z","volume":"149","author":"A Yamaguchi","year":"2023","unstructured":"Yamaguchi A, Saito Y, Narumi K, Furugen A, Takekuma Y, Shinagawa N, Shimizu Y, Dosaka-Akita H, Sugawara M, Kobayashi M. Association between skin immune-related adverse events (irAEs) and multisystem IrAEs during PD-1\/PD-L1 inhibitor monotherapy. J Cancer Res Clin Oncol. 2023;149(4):1659\u201366.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"2052_CR27","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clin Cancer Res. 2023;29(14):2580\u20137.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2052_CR28","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, Sullivan RJ. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706\u201314.","journal-title":"Cancer"},{"issue":"12","key":"2052_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"key":"2052_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fphar.2020.00005","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Wu S, Chen Y, Shao E, Zhuang T, Lu L, Chen X. Fatal adverse events associated with programmed cell death ligand 1 inhibitors: A systematic review and Meta-Analysis. Front Pharmacol. 2020;11:5.","journal-title":"Front Pharmacol"},{"key":"2052_CR31","doi-asserted-by":"publisher","first-page":"627089","DOI":"10.3389\/fmed.2021.627089","volume":"8","author":"X Yu","year":"2021","unstructured":"Yu X, Zhang X, Yao T, Zhang Y, Zhang Y. Fatal adverse events associated with immune checkpoint inhibitors in Non-small cell lung cancer: A systematic review and Meta-Analysis. Front Med (Lausanne). 2021;8:627089.","journal-title":"Front Med (Lausanne)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02052-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:01:53Z","timestamp":1772546513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02052-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2052"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02052-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}